MetaCap

Autolus Therapeutics (AUTL) vs Eikon Therapeutics (EIKN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eikon Therapeutics is the larger company by market cap ($256.8 million vs $241.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-31.27%EIKN-68.40%
+100%+12%-76%
Feb 5, 20261 yearNov 20, 2026
AUTL-36.11%EIKN-67.31%
+77%+1%-74%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus EIKN key metrics
MetricAUTLEIKN
Share price$0.9073$4.74
Market cap$241.65M$256.84M
1-day change-7.38%-0.42%
YTD return-54.41%—
1-year return-26.24%—
5-year return-85.51%—
EPS (TTM)$-0.96$-7.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M—
Revenue growth (YoY)+644.94%—
Net income (latest FY)$-287.53M—
Gross margin-27.83%—
Operating margin-358.87%—
Net margin-381.40%—
52-week high$2.58$17.40
52-week low$0.896$4.72
Distance from 52-week high-64.83%-72.76%
Analyst consensusstrong_buybuy
Avg. price target upside+821.42%+406.33%
Average volume2.07M560.40K
Shares outstanding266.34M54.19M
Employees752384
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Eikon Therapeutics

EIKN stock →

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees

AUTL vs EIKN FAQ

Which is bigger, Autolus Therapeutics or Eikon Therapeutics?

Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $241.65M for Autolus Therapeutics (AUTL).

Are Autolus Therapeutics and Eikon Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons